Literature DB >> 7691498

Travellers' diarrhoea. Which antimicrobial?

Herbert L DuPont1.   

Abstract

For those who venture from highly industrialised areas to developing tropical and semitropical areas, the chance of developing diarrhoea is about 40%. In most cases a bacterial pathogen is responsible for the illness. The antimicrobial agents with the greatest activity against these organisms are cotrimoxazole (trimethoprim/sulfamethoxazole) during the summer months in the interior of Mexico (a region where this agent has been studied extensively), and the fluoroquinolones for other places or other times, until data become available to indicate the appropriateness of cotrimoxazole here as well. Persons at risk should take along with them a drug to treat symptoms of travellers' diarrhoea, and an appropriate antimicrobial agent. At the passage of the third unformed stool, it is recommended that travellers treat themselves with fluids and salt (flavoured mineral water augmented with saltine crackers is sufficient in most cases), symptomatic treatment and antibacterial therapy. Of these, the antimicrobial is the most important component, which is given either as a single large dose or one or twice daily for 3 days. Perhaps optimal therapy for afebrile nondysenteric patients is loperamide in combination with the antibacterial drug. In the face of fever or dysentery, the antimicrobial should be used alone. In special situations where food and beverage restrictions cannot be followed and where the itinerary cannot tolerate even the slightest alterations because of illness, chemoprophylaxis can be considered. The most effective preventive medication in this case is the antimicrobial also used for therapy, taken in half the therapeutic dosage daily while in the area of risk. However, the majority of travellers should not use this approach.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7691498     DOI: 10.2165/00003495-199345060-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  19 in total

1.  Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine.

Authors:  H Peltola; A Siitonen; H Kyrönseppä; I Simula; L Mattila; P Oksanen; M J Kataja; M Cadoz
Journal:  Lancet       Date:  1991-11-23       Impact factor: 79.321

2.  Seasonal variation in etiology of travelers' diarrhea. Finnish-Moroccan Study Group.

Authors:  L Mattila; A Siitonen; H Kyrönseppä; I Simula; P Oksanen; M Stenvik; P Salo; H Peltola
Journal:  J Infect Dis       Date:  1992-02       Impact factor: 5.226

3.  Five versus three days of ofloxacin therapy for traveler's diarrhea: a placebo-controlled study.

Authors:  H L DuPont; C D Ericsson; J J Mathewson; M W DuPont
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

4.  Trimethoprim/sulfamethoxazole remains active against enterotoxigenic Escherichia coli and Shigella species in Guadalajara, Mexico.

Authors:  J C Bandres; J J Mathewson; C D Ericsson; H L Dupont
Journal:  Am J Med Sci       Date:  1992-05       Impact factor: 2.378

Review 5.  Resistance of Shigella, Salmonella, and other selected enteric pathogens to antimicrobial agents.

Authors:  B E Murray
Journal:  Rev Infect Dis       Date:  1986 May-Jun

6.  Treatment of traveler's diarrhea with sulfamethoxazole and trimethoprim and loperamide.

Authors:  C D Ericsson; H L DuPont; J J Mathewson; M S West; P C Johnson; J A Bitsura
Journal:  JAMA       Date:  1990-01-12       Impact factor: 56.272

7.  Treatment of travelers' diarrhea: ciprofloxacin plus loperamide compared with ciprofloxacin alone. A placebo-controlled, randomized trial.

Authors:  D N Taylor; J L Sanchez; W Candler; S Thornton; C McQueen; P Echeverria
Journal:  Ann Intern Med       Date:  1991-05-01       Impact factor: 25.391

8.  Oral aztreonam, a poorly absorbed yet effective therapy for bacterial diarrhea in US travelers to Mexico.

Authors:  H L DuPont; C D Ericsson; J J Mathewson; F J de la Cabada; D A Conrad
Journal:  JAMA       Date:  1992-04-08       Impact factor: 56.272

Review 9.  Bismuth subsalicylate in the treatment and prevention of diarrheal disease.

Authors:  H L DuPont
Journal:  Drug Intell Clin Pharm       Date:  1987-09

10.  A newly recognized cause of travelers' diarrhea: enteroadherent Escherichia coli.

Authors:  J J Mathewson; P C Johnson; H L DuPont; D R Morgan; S A Thornton; L V Wood; C D Ericsson
Journal:  J Infect Dis       Date:  1985-03       Impact factor: 5.226

View more
  3 in total

1.  The health attitudes of young Hispanic women and the health status of their children on the Texas-Mexico border.

Authors:  A Y Russell; M S Williams; P A Farr; A J Schwab; S Plattsmier
Journal:  J Community Health       Date:  1998-06

Review 2.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

3.  Antibiotic resistance pattern of enterotoxigenic Escherichia coli isolated from infants and young adults in Israel.

Authors:  D Turner; N Porat; D Cohen; M Yavzori; D Fraser; N Peled; O Ohana; R Dagan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-09       Impact factor: 3.267

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.